Revolution Medicines (RVMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$3.06
- EPS estimate
- −$2.04
- EPS surprise
- −49.81%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $1.8M
- Reported
- Aug 5, 2026
Revolution Medicines reported a Q2 2026 loss of $3.06 per share on August 5, 2026. That was wider than the estimated loss of $2.04, a miss of 49.81%. The table shows no revenue for the quarter, against an estimate of $1.8 million. A year earlier, in Q2 2025, the loss was $1.31 per share, so the loss more than doubled, up about 134%.
Every quarter in the table is a loss, and losses have widened in each of the last nine quarters. The annual loss per share was $3.10 in 2022, $3.77 in 2023 and $3.57 in 2024, then grew about 66% to $5.91 in 2025. The first half of 2026 alone came to a loss of $5.35 per share, compared with $2.44 a year earlier. The last revenue shown is $742,000 in Q4 2023. Losses were bigger than estimates in 15 of the last 20 quarters, including each of the last nine.
Revolution Medicines reported Q3 between November 5 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show whether the quarterly loss per share keeps widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$2.04 | −$3.06 | −49.81% | $0.00 | SEC |
| Q1 2026 | May 6, 2026 | −$1.84 | −$2.29 | −24.75% | $0.00 | SEC |
| Q4 2025 | Feb 25, 2026 | −$1.58 | −$1.86 | −17.63% | $0.00 | SEC |
| Q3 2025 | Nov 5, 2025 | −$1.42 | −$1.61 | −13.29% | $0.00 | SEC |
| Q2 2025 | Aug 6, 2025 | −$1.14 | −$1.31 | −15.11% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | −$1.09 | −$1.13 | −3.60% | $0.00 | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.99 | −$1.12 | −13.61% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.89 | −$0.94 | −5.24% | $0.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.77 | −$0.81 | −4.56% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.75 | −$0.70 | +6.20% | $0.00 | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.85 | −$1.14 | −33.66% | $742,000.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.01 | −$0.99 | +2.05% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.82 | −$0.92 | −11.80% | $3.8M | SEC |
| Q1 2023 | May 8, 2023 | −$0.80 | −$0.72 | +10.35% | $7.0M | SEC |
| Q4 2022 | Feb 27, 2023 | −$0.82 | −$0.63 | +23.36% | $15.3M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.84 | −$0.87 | −3.35% | $3.4M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.85 | −$0.82 | +3.53% | $9.1M | SEC |
| Q1 2022 | May 9, 2022 | −$0.78 | −$0.78 | −0.65% | $7.6M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.64 | −$0.71 | −11.18% | $9.5M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.63 | −$0.72 | −15.07% | $1.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Revolution Medicines (RVMD) last report earnings?
Revolution Medicines last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did RVMD beat earnings estimates?
No. Revolution Medicines reported EPS of −$3.06 for Q2 2026 against a −$2.04 estimate — a 49.81% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.